Answers are grounded in this paper and cite their sources.
Evaluates the abuse potential and tolerability of sunobinop in comparison to placebo and triazolam.
Drug-liking following sunobinop at a potential therapeutic dose was not different from placebo and was significantly lower compared with triazolam at a recommended dose. In addition, its good tolerability profile suggests sunobinop may be a useful new treatment option, particularly in at-risk populations.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: